SCHEMBL25294154

SCHEMBL25294154

O=C(NS(=O)(=O)c1ccc(C(F)(F)F)cc1)N1CCCC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.51
HPGD P15428 2/20 0.51
MEN1 O00255 1/20 0.51
TSHR P16473 1/20 0.51
HRH3 Q9Y5N1 5/20 0.49
KCNH2 Q12809 1/20 0.48
STS P08842 2/20 0.48
KDM4E B2RXH2 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47
MMP1 P03956 1/20 0.47
KCNA1 Q09470 1/20 0.46
KCNAB1 Q14722 1/20 0.46
MAPT P10636 1/20 0.44
ALKBH2 Q6NS38 1/20 0.44
ALKBH5 Q6P6C2 1/20 0.44
ALKBH3 Q96Q83 1/20 0.44
FTO Q9C0B1 1/20 0.44
SLC1A3 P43003 1/20 0.44
SLC1A2 P43004 1/20 0.44
SLC1A1 P43005 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25293555 0.99 KMT2A (0.54) KMT2AHPGDMEN1TSHRHRH3
SCHEMBL25253834 0.85 LMNA (0.47) HRH3STSMMP1KCNA1KCNAB1
SCHEMBL29178274 0.80 CA12 (0.53) KMT2AMAPTLMNA
Tolpyrramide SCHEMBL667821 0.80 KMT2A (0.64) KMT2AHPGDMEN1KDM4EKCNA1
SCHEMBL25256003 0.79 STS (0.64) KMT2AMEN1TSHRKCNH2STS
SCHEMBL31456338 0.79 ALDH1A1 (0.67) KMT2AHPGDKDM4EKCNA1KCNAB1
SCHEMBL14794998 0.78 POLB (0.54) KMT2AHPGDLMNAPOLB
SCHEMBL24713395 0.77 MMP1 (0.57) KMT2AMEN1HRH3MMP1MAPT
SCHEMBL12459304 0.77 GAA (0.58) KMT2AMEN1KDM4ELMNAPOLB
SCHEMBL1951647 0.76 MMP1 (0.55) KMT2AMEN1MMP1MAPTALKBH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250049736-A1 SULFONAMIDE DERIVATIVES AND THEIR USE AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS THE US SECRETARY DEPARTMENT OF HEALTH (US) 2025-02-13 US disclosed
EP-4448491-A2 N-((ADAMANTAN-1-YL)CARBAMOYL)-BENZENESULFONAMIDE DERIVATIVES AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF HYPERTENSION The United States of America, as represented by the Secretary, Department of Health and Human Services (US) 2024-10-23 EP disclosed
WO-2023114366-A2 SULFONAMIDE DERIVATIVES AND THEIR USE AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) 2023-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250049736-A1 SULFONAMIDE DERIVATIVES AND THEIR USE AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS EPHX1, FAAH, ECE1 KMT2A 2424/4885HPGD 139/4885MEN1 3974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.